Companies › TJ Biopharma
3 active drug programs in 5 registered trials: 3 Phase 2, 1 Phase 1, 1 Phase 3; Oncology, Hematology, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Plonmarlimab Granulocyte-macrophage colony-stimulating factor antagonist | CSF2 | Phase 3 | Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis; Acute Gouty Arthritis | Dec 2026 |
| Uliledlimab CD73 inhibitor | ADORA2A | Phase 2 | Non Small Cell Lung Cancer | Aug 2028 |
| TJ037130 | – | Phase 1 | Solid Tumor | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07208058 | Plonmarlimab | Phase 3 | Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis | Hematology | Dec 2026 |
| NCT07453004 | Plonmarlimab | Phase 2 | Acute Gouty Arthritis | Immunology | Dec 2027 |
| NCT07715747 | TJ037130 | Phase 1 | Solid Tumor | Oncology | Jun 2028 |
| NCT06984588 | Uliledlimab | Phase 2 | Non Small Cell Lung Cancer | Oncology | Aug 2028 |
| NCT07005336 | Uliledlimab | Phase 2 | Non Small Cell Lung Cancer | Oncology | Jan 2029 |
iTeos Therapeutics Innovent Biopharmaceutical Technology (Hangzhou) Nanjing IASO Biotechnology Lepu Biopharma BioRay Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.